Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.

María A Gomis-FontGabriel CabotSilvia López-ArgüelloLaura ZamoranoCarlos JuanBartolome MoyaAntonio Oliver

Published in: The Journal of antimicrobial chemotherapy (2022)

Imipenem/relebactam could be a useful alternative for the treatment of XDR P. aeruginosa infections, potentially reducing resistance development during therapy.

Keyphrases

pseudomonas aeruginosa
drug resistant
gram negative
cystic fibrosis
acinetobacter baumannii
multidrug resistant
stem cells
escherichia coli
biofilm formation
mesenchymal stem cells
bone marrow
cell therapy